The Cancer of the Pancreas Screening-5 CAPS5)Study
About this study
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
- Condition
- Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
- Tested
- Secretin, MRI, Tumor marker gene test with CA19-9
- Sponsor
- Johns Hopkins University
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
- Hereditary Pancreatitis or
- Peutz-Jeghers Syndrome or
- Strong family history of pancreas cancer on one side of the family tree or
- Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A/p16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR
- Endoscopic evaluation of pancreas scheduled
Exclusion 6
- Medical comorbidities or coagulopathy that contraindicate endoscopy
- Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis
- Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope
- Poor performance status
- Inability to provide informed consent
- Pregnancy.
Where
9 sites, 9 recruiting
University of Michigan
Ann Arbor, Michigan, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Dana Farber Cancer Center, Harvard University
Boston, Massachusetts, United States
Case Comprehensive Cancer Center, Case Western Medical Reserve
Cleveland, Ohio, United States
Yale University
New Haven, Connecticut, United States
Columbia University Medical Center
New York, New York, United States
and 3 more sites on ClinicalTrials.gov
Contact
-
Hilary Cosby, RN
Potential match only. Final eligibility is determined by the study team.